Trial Profile

SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camizestrant (Primary) ; Fulvestrant
Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms SERENA-2
Sponsors AstraZeneca; AstraZeneca AB

01 Apr 2025 Planned End Date changed from 28 Mar 2025 to 13 Apr 2026.
23 Jul 2024 This trial has been completed in Germany, according to European Clinical Trials Database.
23 Jul 2024 This trial has been completed in Germany, according to European Clinical Trials Database.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com